SynthesisFrontiers in endocrinology2025
The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Menopausal hormone therapy (MHT) remains a pivotal approach in managing menopausal symptoms; however, its effects on inflammation and cardiovascular risk markers are still under debate. In particular, the combination of medroxyprogesterone acetate (MPA) and conjugated equine estrogens (CEE) has shown variable impacts on inflammatory biomarkers. This systematic review and meta-analysis aimed to synthesize evidence from randomized controlled trials (RCTs) assessing the effects of oral MPA combined with CEE (MPA/CEE) on systemic inflammation in postmenopausal women. Methods: Thirteen RCTs (comprising 16 arms) reporting data on inflammatory markers, including C-reactive protein (CRP), fibrinogen, homocysteine, and interleukin-6 (IL-6), were included, with a total sample size of 2,278 participants. A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals. Subgroup and sensitivity analyses were performed to explore heterogeneity, and publication bias was assessed using Egger's test and trim-and-fill methods. Results: MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². In addition, a significant reduction in fibrinogen levels was observed (WMD = -60.588 mg/dL; 95% CI: -71.436 to -49.741; P < 0.001), especially at MPA doses ≤2.5 mg/day and in women with BMI <25 kg/m². No statistically significant changes were found in homocysteine or IL-6 levels. Conclusion: While MPA/CEE therapy significantly reduces CRP and fibrinogen, key inflammatory and cardiovascular risk markers, these findings suggest a notable protective effect of oral MPA/CEE on inflammation, highlighting the need for individualized therapeutic strategies based on patient risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.